Literature DB >> 23601767

Evaluation of response to induction chemotherapy in esophageal cancer: is barium esophagography or PET-CT useful?

Chee Way Eng1, James Louis Fuqua, Ravinder Grewal, David Ilson, Antoine Cosme David Messiah, Nabil Rizk, Laura Tang, Marc J Gollub.   

Abstract

OBJECTIVE: To determine whether sequential barium esophagograms can predict histopathological response to treatment in esophageal cancer.
MATERIALS AND METHODS: Two radiologists retrospectively reviewed esophagograms pre- and post- chemotherapy in 32 patients for tumor length decrease of at least 15% and luminal width increase of at least 15%. Positron emission tomography-computed tomography (PET-CT) was reviewed for tumor maximum standardized uptake value (SUVmax) decrease of at least 35%. The reference standard was 90% or more tumor necrosis at histopathologic examination of the excised specimen.
RESULTS: Pathologic response ranged from 10% to 100% necrosis. For prediction of tumor response, the sensitivity, specificity, positive and negative predictive values for length ranged from 43.8 to 56.3% and for width from 41.2% to 66.7% and for SUVmax from 47.1% to 53.3%.
CONCLUSION: Performance characteristics for barium esophagograms in our group of patients were similar to PET-CT in predicting tumor response. Both tests were inadequate in predicting tumor response.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23601767     DOI: 10.1016/j.clinimag.2012.08.003

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  2 in total

1.  Application Value of Gastroenterography Combined With CT in the Evaluation of Short-Term Efficacy and Prognosis in Patients With Esophageal Cancer Radiotherapy.

Authors:  Liangliang Xue; Linning E; Zhifeng Wu; Dongqiang Guo
Journal:  Front Surg       Date:  2022-06-09

2.  Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy.

Authors:  Yue Li; Jun Liu; Hong-Xuan Li; Xu-Wei Cai; Zhi-Gang Li; Xiao-Dan Ye; Hao-Hua Teng; Xiao-Long Fu; Wen Yu
Journal:  Front Oncol       Date:  2021-02-19       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.